599 related articles for article (PubMed ID: 31391767)
1. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma.
Akateh C; Black SM; Conteh L; Miller ED; Noonan A; Elliott E; Pawlik TM; Tsung A; Cloyd JM
World J Gastroenterol; 2019 Jul; 25(28):3704-3721. PubMed ID: 31391767
[TBL] [Abstract][Full Text] [Related]
2. Why Adjuvant and Neoadjuvant Therapy Failed in HCC. Can the New Immunotherapy Be Expected to Be Better?
Dikilitas M
J Gastrointest Cancer; 2020 Dec; 51(4):1193-1196. PubMed ID: 32869146
[TBL] [Abstract][Full Text] [Related]
3. The Timing of Liver Transplantation Following Downstaging: Wait of Not to Wait?
Ersan V; Barut B; Yilmaz S
J Gastrointest Cancer; 2020 Dec; 51(4):1152-1156. PubMed ID: 32856230
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Radiation Lobectomy and Immunotherapy for Angioinvasive HCC Resulting in Complete Pathologic Response.
Liou H; Mody K; Boyle AW; Keaveny AP; Croome KP; Burns JM; Harnois DM; Patel TC; Toskich B
Hepatology; 2021 Jul; 74(1):525-527. PubMed ID: 33615518
[No Abstract] [Full Text] [Related]
5. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.
Liu C; Sun L; Xu J; Zhao Y
World J Surg Oncol; 2016 Apr; 14():100. PubMed ID: 27038790
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.
Ye JZ; Chen JZ; Li ZH; Bai T; Chen J; Zhu SL; Li LQ; Wu FX
World J Gastroenterol; 2017 Nov; 23(41):7415-7424. PubMed ID: 29151695
[TBL] [Abstract][Full Text] [Related]
7. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma.
Zhou H; Song T
Biosci Trends; 2021 Jul; 15(3):155-160. PubMed ID: 34039818
[TBL] [Abstract][Full Text] [Related]
8. What Should Be the Rules for Downstaging for Hepatocellular Carcinoma?
Dirican A; Karakas S
J Gastrointest Cancer; 2020 Dec; 51(4):1148-1151. PubMed ID: 32839945
[TBL] [Abstract][Full Text] [Related]
9. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.
Llovet JM; De Baere T; Kulik L; Haber PK; Greten TF; Meyer T; Lencioni R
Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):293-313. PubMed ID: 33510460
[TBL] [Abstract][Full Text] [Related]
10. Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma.
Urquijo-Ponce JJ; Alventosa-Mateu C; Latorre-Sánchez M; Castelló-Miralles I; Diago M
World J Gastroenterol; 2024 May; 30(19):2512-2522. PubMed ID: 38817666
[TBL] [Abstract][Full Text] [Related]
11. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma.
Tung-Ping Poon R; Fan ST; Wong J
Ann Surg; 2000 Jul; 232(1):10-24. PubMed ID: 10862190
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy for hepatocellular carcinoma after curative treatment.
Jeng WJ; Lin CC; Chen WT; Sheen IS; Lin CY; Lin SM
Dig Dis; 2014; 32(6):747-54. PubMed ID: 25376293
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant and adjuvant treatment approaches for hepatocellular carcinoma: future outlook.
Sahin IH; Khalil L; Millett R; Kaseb A
Chin Clin Oncol; 2021 Feb; 10(1):7. PubMed ID: 33440948
[TBL] [Abstract][Full Text] [Related]
14. Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma.
Pinato DJ; Fessas P; Sapisochin G; Marron TU
Hepatology; 2021 Jul; 74(1):483-490. PubMed ID: 33369758
[No Abstract] [Full Text] [Related]
15. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
Choi J; Jo C; Lim YS
Hepatology; 2021 Feb; 73(2):661-673. PubMed ID: 32324905
[TBL] [Abstract][Full Text] [Related]
16. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
17. The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review.
Lau WY; Lai EC; Lau SH
Hepatobiliary Pancreat Dis Int; 2009 Apr; 8(2):124-33. PubMed ID: 19357024
[TBL] [Abstract][Full Text] [Related]
18. Pediatric Hepatocellular Carcinoma.
Varol Fİ
J Gastrointest Cancer; 2020 Dec; 51(4):1169-1175. PubMed ID: 32856229
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Liver Transplantation for Hepatocellular Carcinoma Beyond the University of California San Francisco Criteria: A Single-center Experience.
Victor DW; Monsour HP; Boktour M; Lunsford K; Balogh J; Graviss EA; Nguyen DT; McFadden R; Divatia MK; Heyne K; Ankoma-Sey V; Egwim C; Galati J; Duchini A; Saharia A; Mobley C; Gaber AO; Ghobrial RM
Transplantation; 2020 Jan; 104(1):113-121. PubMed ID: 31233480
[TBL] [Abstract][Full Text] [Related]
20. An Overview of Clinical Trials in the Treatment of Resectable Hepatocellular Carcinoma.
Nevarez NM; Chang GY; Yopp AC
Surg Oncol Clin N Am; 2023 Jan; 32(1):101-117. PubMed ID: 36410911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
